PTGX Protagonist Therapeutics, Inc

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Development and commercialization of pharmaceutical and biological products subject to extensive U.S. and EU regulatory oversight
• • New filings: July 2025 NDA by Johnson & Johnson for Icotyde; January 2026 NDA by Protagonist and Takeda for rusfertide for polycythemia vera
• • Strategic focus: Emphasis on global clinical trials and international marketing with associated geopolitical and regulatory risk exposure
• • Quantitative metric: Introduction of new U.S. tariffs up to 100% on branded pharmaceuticals announced September 2025, potential cost impact
• • Noteworthy fact: May 2025 executive order on most-favored-nation drug pricing aiming to align U.S. prices with OECD countries affecting pricing strategy

Risk Factors

• • Regulatory risk: FDA approval timing and receipt of up to $400M payments plus $75M milestone under Takeda Collaboration Agreement opt-out in 2026
• • Macroeconomic risk: exposure to geopolitical instability, high interest rates, and trade policy changes potentially impacting operations and FDA agency functioning
• • Operational risk: reliance on third-party clinical trial sites and contract manufacturers with accrual variability affecting R&D expense accuracy
• • Market disruption risk: competition in obesity and oral hepcidin therapy markets with development of PN-477, PN-458, and PN-8047 pipeline candidates
• • Financial risk: cumulative net losses of $470.7M through 2025 with increased R&D expenses of $159.3M, pressuring liquidity and funding needs

Management Discussion & Analysis

• • Revenue not explicitly disclosed; milestone payments: $165M (2025), $300M upfront (2024), $25M milestone (2025)
• • Net loss $130.1M in 2025 vs net income $275.2M in 2024; no margin % figures provided
• • Cash from operations $57.7M (2025) down from $184.2M (2024), driven by milestone-related cash flows
• • Cash flow investing: $49.3M (2025) vs $299.5M (2024) used, mainly marketable securities transactions and capex $1.6M (2025)
• • Financing cash inflows $22.9M (2025) vs $25.9M (2024) from stock issuances; $0 buybacks or dividends mentioned
• • Outlook: Cash $646M sufficient for at least 12 months; potential future funding needs depend on pipeline advancement and collaborations

What are the latest PTGX SEC filings in 2026?

Protagonist Therapeutics, Inc (PTGX) has filed a 10-K annual report on February 25, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on August 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did PTGX file its most recent 10-K annual report?

Protagonist Therapeutics, Inc (PTGX) filed its most recent 10-K annual report on February 25, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view PTGX 10-Q quarterly reports?

Protagonist Therapeutics, Inc (PTGX)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every PTGX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has PTGX filed recently?

Protagonist Therapeutics, Inc (PTGX)'s most recent 8-K was filed on August 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find PTGX insider trading activity (Form 4)?

SignalX aggregates every PTGX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does PTGX file with the SEC?

Protagonist Therapeutics, Inc (PTGX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new PTGX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Protagonist Therapeutics, Inc (PTGX).

What is PTGX's SEC CIK number?

Protagonist Therapeutics, Inc (PTGX)'s SEC CIK (Central Index Key) number is 1377121. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1377121 to look up all PTGX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find PTGX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Protagonist Therapeutics, Inc (PTGX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.